Shopping Cart
- Remove All
- Your shopping cart is currently empty
ABP-102 (CT P72) is a tetravalent IgG1-[L]-scFv bispecific t-cell adduct (BiTE) that acts as a CD3 modulator and selective HER2 modulator for the selective targeting of HER2 overexpressing tumors. ABP-102 showed cytotoxicity in HER2-overexpressing models of breast and gastric cancers, while significantly decreasing activity against HER2 low level cells, twice as effective as rununmotamab.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | Inquiry | Backorder | |
5 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | ABP-102 (CT P72) is a tetravalent IgG1-[L]-scFv bispecific t-cell adduct (BiTE) that acts as a CD3 modulator and selective HER2 modulator for the selective targeting of HER2 overexpressing tumors. ABP-102 showed cytotoxicity in HER2-overexpressing models of breast and gastric cancers, while significantly decreasing activity against HER2 low level cells, twice as effective as rununmotamab. |
In vitro | ABP-102/CT-P72 achieves potent cytotoxicity in HER2-overexpressing breast and gastric cancer models while significantly reducing activity against HER2-low cells, addressing a key limitation of prior HER2-targeted T-cell engagers[1]. ABP-102/CT-P72 achieved up to twice the tumor suppression compared to a biosimilar of runimotamab (a benchmark HER2 x CD3 bispecific antibody)[1].By engineering functionally monovalent CD3 binding, ABP-102/CT-P72 significantly reduced cytokine release in HER2-low models while maintaining strong cytotoxicity in HER2-high models[1]. |
In vivo | Dose escalation studies in cynomolgus monkeys showed that ABP-102/CT-P72 was well tolerated even at doses over 180 times higher than the maximum tolerated dose of the parental antibody [1]. |
Alias | CTP72, CT P72, ABP102 |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.